vaccin
remain
econom
effect
mean
respiratori
diseas
caus
influenza
virus
base
circul
virus
popul
trival
vaccin
strain
develop
use
influenza
viru
protect
accept
current
avail
strategi
intramuscular
administr
inactiv
vaccin
produc
eggbas
manufactur
system
effect
hamper
limit
capac
flexibl
howev
vaccin
strain
must
frequent
adapt
match
circul
virus
throughout
world
addit
level
antibodi
induc
inactiv
vaccin
observ
decreas
period
therefor
altern
strategi
develop
broadli
crossprotect
safe
effect
vaccin
influenza
viral
infect
promin
import
matrix
protein
highli
conserv
among
influenza
viru
strain
indic
attract
target
develop
univers
vaccin
previou
studi
variou
construct
vaccin
develop
test
includ
recombin
escherichia
coli
e
coli
express
fusion
protein
adenovir
vector
express
protein
plasmid
dna
encod
peptid
encod
abl
elicit
protect
immun
respons
mice
howev
drawback
vaccin
low
immunogen
addit
would
requir
intramuscular
inject
therefor
mani
strategi
appli
focus
increas
immunogen
vaccin
exampl
fusion
differ
carrier
molecul
like
human
papilloma
viru
l
protein
keyhol
limpet
hemocyanin
flagellin
furthermor
vaccin
differ
adjuv
rout
administr
appli
evalu
protect
diverg
strain
influenza
virus
mice
immun
mucos
viru
like
particl
vlp
adjuv
cholera
toxin
ct
demonstr
better
protect
compar
mice
subject
parenter
immun
howev
due
advers
effect
ct
human
investig
attempt
identifi
nontox
subunit
adjuvant
remov
either
subunit
subunit
b
e
coli
express
cholera
toxin
subunit
fuse
dfragment
staphylococcu
aureu
show
adjuv
effect
without
reactogen
subunit
mucos
vaccin
although
chemic
genet
conjug
may
present
nativ
tetramer
form
extracellularli
access
antigen
express
surfac
bacteria
better
recogn
immun
system
intracellular
thu
choic
deliveri
vehicl
also
import
concern
potenti
mucos
vaccin
recent
lactic
acid
bacteria
lab
present
influenza
viru
antigen
studi
mucos
immun
lab
attract
deliveri
system
live
vaccin
vector
shigella
salmonella
listeria
consid
safe
exhibit
adjuvantlik
effect
mucos
system
immun
anchor
target
protein
cell
surfac
lab
primarili
intend
use
mucos
vaccin
transmembran
protein
pgsa
one
synthetas
complex
bacillu
subtili
wellstudi
anchor
protein
abl
fuse
target
protein
c
terminu
stabil
complex
anchor
cell
membran
sinc
highli
conserv
promis
target
univers
vaccin
strong
mucos
adjuv
studi
develop
construct
use
consensu
gene
reconstitut
analysi
influenza
virus
transmembran
domain
without
fusion
achiev
use
novel
express
vector
express
pgsa
gene
product
anchor
matrix
target
antigen
display
surfac
lactobacillu
casei
oral
intranas
administr
recombin
l
casei
induc
system
mucos
immun
respons
potenti
protect
lethal
challeng
diverg
influenza
subtyp
total
femal
balbc
mice
week
old
purchas
samtako
seoul
korea
hous
ventil
cage
mice
manag
pellet
feed
tap
water
ad
libitum
maintain
specificpathogenfre
environ
effort
made
minim
suffer
follow
approv
institut
anim
care
use
committe
biolead
corpor
daejeon
south
korea
protocol
number
immun
anim
conduct
biosafeti
level
bsl
laboratori
facil
mice
divid
experiment
set
consist
subset
oral
intranas
administr
contain
group
set
mice
per
group
one
set
mice
lung
histopatholog
immunohistochemistri
last
contain
mice
per
group
mice
ctl
respons
concentr
recombin
l
casei
determin
coloni
form
unit
cfu
subset
group
receiv
cfu
casei
casei
remain
two
group
receiv
concentr
pkvpgsal
casei
pb
oral
via
intragastr
lavag
day
similarli
cfu
recombin
cell
administ
suspens
nostril
lightli
anesthet
mice
day
blood
sampl
collect
retroorbit
plexu
day
sera
separ
centrifug
minut
store
analysi
day
mice
group
randomli
sacrif
collect
iga
sampl
lung
intestin
store
analysi
spleen
collect
asept
day
analysi
ctl
respons
randomli
mice
one
set
rest
mice
set
maintain
month
date
last
boost
measur
longlast
immun
respons
protect
efficaci
avian
influenza
virus
apuerto
aaquat
aaquat
use
studi
kindli
provid
dr
youngki
choi
colleg
medicin
medic
research
institut
chungbuk
nation
univers
cheongju
republ
korea
virus
propag
allanto
fluid
chicken
embryo
mous
lethal
dose
determin
naiv
balbc
mice
ether
narcosisanesthet
mice
intranas
infect
time
challeng
virus
pb
six
mice
group
sacrif
dpi
check
viru
titer
lung
mice
remain
group
use
surviv
mice
monitor
everi
altern
day
fix
time
point
measur
weight
loss
surviv
mice
euthan
moribund
ie
weight
loss
ruffl
fur
shiver
tachypnea
respiratori
distress
hypothermia
poorli
respons
extern
stimuli
remain
consid
surviv
number
final
monitor
surviv
mice
human
euthan
use
inhal
minut
day
final
vaccin
mice
one
set
challeng
measur
long
last
immun
respons
challeng
test
conduct
insid
approv
facil
appropri
condit
studi
e
coli
use
clone
l
casei
use
surfac
express
target
protein
bacteria
grown
lb
mr
media
respect
plasmid
pkvpaldpgsa
harbor
pgsa
gene
bacillu
subtili
use
construct
surfac
display
plasmid
kind
gift
biolead
corpor
daejeon
south
korea
gene
encod
consensu
sequenc
span
residu
extracellular
cytoplasm
domain
without
transmembran
domain
influenza
viru
gener
consensu
sequenc
creat
base
common
amino
acid
posit
align
synthes
use
templat
construct
plasmid
casei
casei
clone
describ
previous
gene
modifi
ad
kpn
site
termin
sal
termin
clone
polymeras
chain
reaction
pcr
perform
amplifi
gene
use
primer
pair
similarli
bamh
site
termin
kpn
site
termin
end
ad
gene
use
primer
acccgatgatcttggagc
modifi
gene
ligat
easi
vector
invitrogen
seoul
korea
gene
digest
kpn
isal
bamh
ikpn
digest
ligat
plasmid
vector
pkvpgsa
construct
similarli
ligat
construct
ligat
product
transform
e
coli
compet
cell
previous
describ
use
electropor
method
profil
recombin
plasmid
confirm
restrict
endonucleas
digest
dna
sequenc
solgent
seoul
korea
confirm
plasmid
transform
l
casei
electropor
name
casei
casei
recombin
l
casei
contain
pgsa
gene
grown
hour
cell
harvest
centrifug
minut
follow
wash
two
time
steril
phosphatebuff
salin
pb
bacteri
lyse
perform
sonic
centrifug
minut
cell
wall
cytoplasm
fraction
separ
centrifug
hour
pellet
cell
wall
resuspend
sarcosol
contain
mm
phenylmethylsulfonyl
fluorid
pmsf
sigmaaldrich
st
loui
usa
proteas
inhibitor
fraction
analyz
western
blot
describ
previous
immun
detect
fusion
protein
membran
probe
rabbit
anticholera
toxin
abcam
uk
rabbit
antipgsa
rabbit
antibodi
rabbit
antipgsa
rabbit
antibodi
use
experi
gener
im
inocul
klhconjug
pgsa
peptid
rabbit
respect
two
time
weeksinterv
membran
react
dilut
antirabbit
immunoglobulin
g
conjug
horseradish
peroxidas
igg
hrp
final
target
protein
detect
use
westzol
plu
western
blot
detect
system
intron
biotechnolog
gyeonggido
korea
visual
enhanc
chemiluminesc
ecl
investig
express
surfac
l
casei
recombin
l
casei
grown
hour
mr
broth
bacteria
harvest
centrifug
minut
wash
three
time
steril
phosphatebuff
salin
contain
pbst
probe
polyclon
rabbit
rabbit
antict
antibodi
overnight
follow
anoth
wash
cell
treat
fluorescein
isothiocyan
fitc
conjug
antirabbit
igg
antibodi
burlingam
ca
usa
hour
final
cell
analyz
flow
cytometri
becton
dickinson
oxnard
ca
usa
immunofluoresc
cell
prepar
condit
describ
flow
cytometri
pgsal
casei
use
neg
control
immunofluores
analysi
examin
use
carl
zeiss
axioskop
fluoresc
microscop
antibodi
titer
measur
enzymelink
immunosorb
assay
elisa
use
serum
mucos
sampl
vaccin
mice
first
immunosorb
plate
nunc
incub
ngwell
purifi
protein
overnight
recombin
protein
use
studi
purifi
e
coli
next
well
block
skim
milk
hour
rt
wash
five
time
pbst
treat
dilut
serum
sampl
triplic
detect
igg
undilut
tissu
homogen
supernat
detect
local
iga
incub
hour
wash
three
time
goat
antimous
igg
hrp
sigma
antimous
iga
ad
well
incub
addit
hour
follow
anoth
round
wash
plate
react
substrat
solut
contain
tetramethylbenzidin
allow
preced
reaction
minut
ad
stop
solut
optic
densiti
od
measur
use
elisa
autoread
molecular
devic
develop
count
cytokin
perform
elispot
describ
previous
briefli
day
isol
splenocyt
elispot
plate
coat
monoclon
antimous
captur
antibodi
pb
incub
overnight
plate
wash
pb
block
solut
contain
complet
rpmi
medium
fetal
bovin
serum
ad
invitrogen
carlsbad
ca
usa
incub
hour
rt
spleen
vaccin
mice
isol
asept
ad
cellswel
media
contain
protein
peptid
slltevetptrngweckcsd
medium
neg
control
phytohemagglutinin
posit
control
invitrogen
carlsbad
ca
usa
ad
cell
stimul
plate
incub
hour
plate
sequenti
treat
biotinyl
antimous
antibodi
streptavidinhorseradish
peroxidas
substrat
solut
final
spot
count
use
immunoscan
entri
analyz
cellular
technolog
shaker
height
usa
lung
collect
asept
viru
titer
determin
tissu
cultur
infecti
dose
describ
previous
briefli
lung
tissu
homogen
pb
contain
antibiot
penicillin
streptomycin
antimycot
fungizon
compound
gibco
grand
island
ny
usa
mechan
homogen
lung
sampl
centrifug
minut
remov
cellular
debri
storag
mdck
cell
inocul
serial
dilut
sampl
incub
humid
atmospher
hour
absorpt
media
remov
overlay
medium
contain
chloromethyl
keton
tpck
trypsin
thermo
fisher
scientif
rockford
usa
ad
infect
cell
incub
hour
viral
cytopath
effect
observ
daili
titer
determin
ha
test
viral
titer
sampl
express
tissu
infect
dose
use
reedmuench
method
histopatholog
lung
tissu
collect
dpi
ether
narcosisanesthet
mice
tissu
immedi
fix
formalin
contain
neutral
buffer
embed
paraffin
wax
section
thick
use
microtom
machin
mount
onto
slide
stain
eosin
stain
histopatholog
chang
examin
light
microscopi
previous
describ
furthermor
slide
stain
use
immunoperoxidas
method
antibodi
rabbit
direct
matrix
influenza
viru
goatantirabbit
igg
hrp
sigmaaldrich
st
loui
usa
use
secondari
antibodi
detect
viru
infect
cell
respect
tissu
data
present
mean
standard
deviat
sd
repres
least
three
independ
experi
differ
group
analyz
analysi
varianc
anova
mean
compar
student
ttest
pvalu
less
regard
signific
result
percent
initi
bodi
weight
also
compar
use
student
test
comparison
surviv
done
logrank
test
use
graphpad
prism
version
pgsaexpress
vector
use
construct
plasmid
contain
highli
conserv
consensu
gene
without
cholera
toxin
subunit
fig
plasmid
transform
l
casei
cell
express
level
monitor
immunoblot
use
antipgsa
antict
polyclon
antibodi
data
shown
determin
cellular
local
protein
express
surfac
l
casei
via
cell
wall
anchor
protein
pgsa
membran
cytoplasm
fraction
subject
western
blot
analysi
expect
fusion
protein
detect
antipgsa
antict
polyclon
antibodi
membran
cytoplasm
fraction
fig
lane
immunoreact
perform
antipgsa
band
repres
size
fuse
protein
detect
reaction
antict
antibodi
band
detect
fig
lane
find
may
result
degrad
occur
membran
fraction
procedur
fluorescenceactiv
cell
sort
fac
immunofluoresc
label
cell
use
verifi
local
fusion
protein
surfac
l
casei
flow
cytometr
analysi
use
rabbit
antict
antibodi
reveal
increas
level
fluoresc
intens
casei
casei
cell
compar
control
l
casei
cell
fig
immunofluoresc
microscopi
also
show
recombin
bacteria
harbor
immunostain
posit
found
control
cell
result
demonstr
recombin
l
casei
could
effici
display
fusion
protein
surfac
use
pgsa
membran
anchor
protein
preliminari
experi
conduct
determin
dose
schedul
casei
vaccin
candid
influenza
viru
protect
data
shown
character
immunogen
l
casei
surfacedisplay
balbc
mice
immun
nasal
dose
oral
dose
recombin
live
casei
casei
bacteria
neg
control
mice
immun
l
casei
harbor
parent
plasmid
pkvpgsa
pgsal
casei
pb
serum
sampl
collect
day
analyz
elisa
use
protein
purifi
e
coli
coat
antigen
first
seri
immun
compar
low
level
serum
igg
detect
oral
immun
group
howev
high
antibodi
level
detect
shortli
second
seri
immun
group
induc
serum
igg
signific
level
compar
group
neg
control
fig
b
although
conjug
expect
adjuv
function
signific
level
antibodi
detect
nasal
oral
vaccin
fig
b
right
panel
comparison
oral
group
nasal
immun
group
show
higher
level
serum
igg
specif
assess
mucos
immun
respons
local
iga
level
determin
elisa
lung
intestin
tissu
collect
day
immun
examin
use
protein
coat
antigen
rout
vaccin
casei
induc
significantli
increas
level
mucos
iga
compar
casei
control
group
howev
expect
higher
level
antibodi
titer
detect
site
inocul
remot
site
similar
pattern
antibodi
respons
observ
rout
immun
casei
group
domin
fig
data
demonstr
cholera
toxin
subunit
result
signific
enhanc
igg
mucos
iga
level
compar
alon
control
immun
pgsal
casei
pb
determin
whether
mucos
vaccin
l
casei
surfacedisplay
could
induc
cellular
immun
elispot
perform
splenocyt
vaccin
mice
stimul
recombin
protein
peptid
cytokin
elispot
develop
spot
count
measur
differ
ctl
respons
group
cell
mice
immun
casei
show
signific
level
respons
stimul
protein
peptid
fig
similarli
observ
administ
group
casei
casei
show
detect
level
secret
splenocyt
follow
stimul
either
protein
peptid
fig
secret
cell
also
observ
mice
immun
oral
casei
casei
fig
although
level
lower
group
signific
control
group
immun
pgsal
casei
show
background
spot
level
intranas
oral
group
find
indic
highli
conserv
induc
secret
cell
respons
mucos
deliveri
l
casei
conjug
enhanc
cell
mediat
immun
may
contribut
broaden
protect
immun
known
potenti
target
develop
broad
spectrum
influenza
vaccin
minimum
variabl
confirm
variabl
sequenc
challeng
virus
use
studi
compar
influenza
subtyp
avail
us
nation
center
biotechnolog
inform
ncbi
consensu
sequenc
particularli
whole
conserv
ecto
portion
cytoplasm
domain
cd
although
entir
cd
includ
vaccin
construct
tabl
found
virus
use
studi
contain
mismatch
amino
acid
among
amino
acid
compar
studi
evalu
efficaci
vaccin
week
final
immun
mice
challeng
aaquat
influenza
viru
subtyp
homolog
consensu
sequenc
mice
immun
oral
casei
casei
show
protect
respect
similarli
immun
group
confer
lethal
infect
highli
virul
viru
contrast
none
unimmun
mice
surviv
lethal
infect
fig
b
right
panel
morbid
increas
mice
immun
via
oral
rout
wherea
mice
receiv
immun
casei
lost
initi
bodi
weight
start
recov
day
post
infect
dpi
complet
recov
day
fig
b
left
panel
next
evalu
protect
effici
vaccin
candid
apuerto
contain
mismatch
amino
acid
rel
consensu
sequenc
set
vaccin
mice
challeng
viru
shown
figur
mice
immun
rout
exhibit
higher
level
protect
oral
immun
group
mice
immun
casei
show
significantli
higher
level
protect
compar
mice
immun
casei
fig
right
panel
unimmun
mice
lost
bodi
weight
die
dpi
mice
immun
casei
lost
approxim
bodi
weight
wherea
mice
immun
casei
lost
initi
bodi
weight
dpi
recov
slowli
mice
immun
casei
fig
left
panel
anoth
set
vaccin
mice
infect
check
rang
protect
abil
vaccin
induc
immun
respons
sequenc
contain
mismatch
rel
consensu
sequenc
mice
immun
casei
show
neglig
bodi
weight
loss
gradual
recoveri
compar
mice
immun
casei
unimmun
mice
oral
rout
fig
f
left
panel
none
unimmun
mice
surviv
wherea
mice
immun
casei
via
oral
rout
surviv
respect
surviv
rate
mice
immun
casei
oral
rout
respect
fig
f
right
panel
breadth
protect
vaccin
diverg
influenza
subtyp
also
evalu
set
immun
mice
challeng
high
pathogen
avian
influenza
hpai
contain
amino
acid
mismatch
rel
consensu
sequenc
mice
immun
via
oral
rout
casei
show
higher
protect
efficaci
respect
compar
mice
immun
casei
rate
respect
fig
h
right
panel
regard
morbid
mice
immun
casei
show
lower
morbid
mice
immun
casei
fig
h
left
panel
one
set
vaccin
mice
challeng
aaquat
viru
contain
mismatch
rel
consensu
sequenc
bodi
weight
surviv
observ
dpi
shown
figur
j
unimmun
mice
lost
much
bodi
weight
mice
immun
casei
casei
fig
j
left
panel
mice
immun
casei
rout
show
significantli
higher
level
protect
influenza
viru
group
fig
j
right
panel
taken
togeth
result
indic
immun
casei
induc
immun
respons
confer
signific
level
protect
diverg
subtyp
influenza
virus
contain
mismatch
amino
acid
rang
consensu
regardless
whether
complet
partial
viru
titer
lung
challeng
mice
measur
estim
replic
dpi
mice
immun
via
oral
rout
casei
casei
challeng
influenza
subtyp
dpi
mice
sacrif
randomli
group
lung
viru
titer
measur
use
method
mice
immun
casei
lower
titer
dpi
significantli
reduc
viral
replic
dpi
compar
mice
immun
casei
control
group
time
fig
reduc
viral
titer
lung
observ
group
mice
immun
via
rout
rel
mice
immun
via
oral
rout
particularli
day
post
infect
fig
reduc
titer
may
due
rout
vaccin
challeng
titer
correl
surviv
result
lethal
infect
taken
togeth
result
demonstr
consensu
protein
fuse
afford
better
protect
rout
potent
oral
rout
immun
regard
protect
lethal
challeng
diverg
influenza
subtyp
histopatholog
immunohistochemistri
perform
corrobor
lung
viru
titer
find
dpi
lung
randomli
collect
group
one
set
fix
stain
eosin
examin
light
microscop
shown
figur
clear
sign
profound
pulmonari
inflamm
observ
lung
mice
treat
pb
pgsal
casei
oral
rout
administr
wherea
lung
mice
immun
casei
show
remark
pulmonari
inflamm
compar
caseitr
mice
fig
middl
left
panel
immunohistochemistri
immunoperoxidas
method
antibodi
direct
matrix
influenza
viru
use
detect
viru
infect
cell
respect
tissu
viru
antigen
epitheli
cell
appear
brown
color
nucleu
cytoplasm
shown
figur
day
pi
numer
virusinfect
cell
detect
control
casei
vaccin
mice
wherea
highli
reduc
number
antigen
posit
cell
found
mice
vaccin
casei
oral
immun
group
fig
right
panel
result
indic
mice
immun
casei
develop
immun
respons
strong
enough
inhibit
viru
replic
promot
surviv
mice
lethal
infect
influenza
durat
protect
import
criterion
potenti
vaccin
thu
longev
immun
induc
investig
detect
serum
igg
mucos
iga
elisa
significantli
increas
level
serum
igg
well
lung
intestin
iga
observ
day
vaccin
fig
c
compar
pb
pgsal
casei
group
mice
challeng
aaquat
bodi
weight
chang
surviv
monitor
dpi
unimmun
mice
show
bodi
weight
loss
fig
left
panel
die
day
post
infect
oral
group
contrast
mice
immun
casei
show
neglig
bodi
weight
loss
recov
dpi
surviv
immun
group
fig
right
panel
surviv
oral
immun
group
fig
right
panel
result
indic
mucos
vaccin
confer
protect
lethal
infect
month
final
immun
mucos
immun
system
first
immunolog
barrier
pathogen
invad
bodi
via
mucos
surfac
thu
induct
mucos
immun
necessari
ensur
protect
multipl
subtyp
influenza
viru
respiratori
viru
influenza
respons
annual
season
epidem
worldwid
occasion
pandem
caus
emerg
novel
subtypesstrain
deriv
reassort
avian
porcin
virus
current
influenza
vaccin
provid
strainspecif
protect
thu
crucial
establish
broadli
crossprotect
influenza
vaccin
antigen
well
conserv
among
influenza
virus
consid
promis
target
induct
crossprotect
differ
subtyp
howev
goal
develop
first
line
defens
effect
elimin
pathogen
mucos
surfac
influenza
matrix
rel
well
conserv
among
influenza
subtyp
consid
promis
influenza
vaccin
antigen
consist
follow
three
structur
domain
extracellular
domain
transmembran
domain
cytoplasm
tail
domain
extracellular
cytoplasm
domain
well
conserv
among
influenza
virus
play
import
role
viral
assembl
morphogenesi
use
studi
develop
consensu
deriv
analysi
sequenc
subtyp
databas
consid
previou
find
extracellular
domain
particularli
aa
highli
conserv
among
influenza
viru
subtyp
recogn
epitop
induct
monoclon
antibodi
could
protect
influenza
viru
infect
backbon
sequenc
viru
use
possibl
homolog
among
subtyp
chang
posit
kept
unchang
conserv
epitop
aa
shown
sequenc
align
consensu
sequenc
mismatch
among
subtyp
use
studi
tabl
moreov
incorpor
adjuv
consid
essenti
boost
interact
vaccin
mucos
immun
system
variou
adjuv
liposom
nanoparticl
immunostimul
complex
iscom
studi
found
improv
immun
respons
efficaci
optim
despit
potenti
mucos
adjuv
use
cholera
toxin
ct
vaccin
limit
innat
toxic
thu
toxic
ct
would
separ
adjuvant
could
use
vaccin
adjuv
studi
shown
construct
consist
fuse
cholera
toxin
subunit
along
strong
adpribosyl
agent
dimer
dfragment
staphylococcu
aureu
protein
vaccin
elicit
complet
protect
reduc
morbid
retain
adjuv
function
ct
without
toxic
side
effect
reactogen
site
administr
bind
accumul
nervou
tissu
base
previou
find
hypothes
consensu
fragment
fuse
potent
mucos
adjuv
may
induc
broad
protect
immun
diverg
subtyp
influenza
viru
studi
use
whole
protein
adp
ribosyltransferas
consist
three
distinct
subdomain
residu
residu
residu
report
lack
ctb
strong
adjuv
activ
without
toxic
enhanc
iga
igg
antibodi
respons
well
ctl
activ
develop
univers
mucos
influenza
vaccin
conserv
peptid
potent
adjuv
recombin
l
casei
display
fuse
without
construct
mucos
deliveri
wide
use
live
vaccin
vehicl
lab
pgsa
gene
use
studi
anchor
display
surfac
lab
deriv
pgsbca
enzym
complex
bacillu
subtili
consist
transmembran
domain
near
nterminu
domain
locat
outsid
cell
membran
thu
pgsa
abl
cross
cell
wall
display
heterolog
protein
fuse
cterminu
develop
vaccin
test
two
major
rout
found
vaccin
casei
abl
induc
significantli
higher
level
serum
igg
fig
b
mucos
iga
fig
compar
casei
confer
protect
diverg
influenza
subtyp
phylogenet
group
group
fig
studi
also
reveal
administr
superior
oral
rout
vaccin
consist
observ
may
two
possibl
reason
explain
phenomenon
first
challeng
rout
vaccin
specif
mucos
iga
prevent
viral
colon
respiratori
tract
second
volum
inocula
time
lower
oral
inocul
may
allow
concentr
form
antigen
present
immun
cell
greater
level
serum
igg
mucos
iga
detect
intranas
immun
mice
immun
oral
fig
altern
explan
could
antigen
process
andor
present
differ
immun
cell
two
mucos
compart
importantli
studi
demonstr
first
time
mucos
immun
lab
surfacedisplay
vaccin
candid
induc
broad
protect
challeng
diverg
influenza
subtyp
howev
mechan
ab
mediat
broad
protect
fulli
understood
previou
studi
demonstr
ab
nterminu
particularli
posit
inhibit
replic
influenza
viru
studi
reveal
iggmedi
cellular
cytotox
phagocytosi
induc
remov
infect
cell
progeni
viru
bud
spread
support
find
lung
viru
titer
immunohistochemistri
data
detect
dpi
challeng
experi
therefor
studi
combin
respons
ab
nterminu
sequenc
conserv
among
challeng
virus
tabl
may
protect
diverg
influenza
subtyp
mucos
immun
recombin
lab
vaccin
candid
moreov
cellular
immun
respons
play
import
role
control
viral
replic
examin
cytokin
respons
elispot
assay
significantli
higher
level
detect
respons
stimul
protein
peptid
mice
immun
casei
compar
level
mice
casei
control
group
fig
c
similarli
substanti
high
level
observ
mice
immun
casei
upon
stimul
protein
peptid
fig
result
support
find
antibodi
cellmedi
cytotox
specif
antigen
antivir
activ
induc
monomer
three
copi
fuse
togeth
result
indic
adjuv
fuse
induc
immun
respons
mice
protect
diverg
influenza
subtyp
regard
result
signific
use
adjuv
function
vaccin
candid
clinic
protect
paramet
vaccin
perform
assess
evalu
immunogen
recombin
lab
vaccin
basi
paramet
reduct
patholog
lesion
viru
shed
studi
low
titer
challeng
viru
titrat
lung
vaccin
casei
wherea
challeng
viru
could
detect
higher
titer
mock
mice
vaccin
casei
fig
reduc
gross
histopatholog
lesion
consist
viral
infect
primari
paramet
indic
influenza
vaccin
efficaci
demonstr
vaccin
casei
remark
limit
sever
damag
inhibit
viral
replic
accumul
inflammatori
cell
viru
antigen
lung
alveolar
tissu
rel
sever
unimmun
mice
mice
vaccin
casei
fig
studi
demonstr
first
time
recombin
l
casei
express
induc
longlast
immun
confer
protect
lethal
infect
influenza
even
month
final
vaccin
fig
import
success
vaccin
similar
result
observ
previou
studi
vlp
confer
longterm
immun
cross
protect
antibodi
sera
mucos
site
long
live
conclus
find
reveal
mucos
immun
mice
recombin
l
casei
express
induc
system
local
well
cellmedi
immun
respons
diverg
influenza
viru
subtyp
thu
recombin
l
casei
express
consensu
mucos
vaccin
may
promis
vaccin
candid
influenza
pandem
prepared
